GlassScriptPhysician profile
Kayla Scott
NPI 1518503747
$4,032.20
in general payments reported to CMS, 2019-2025
41 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.92 · 2022: $103 · 2023: $1,760 · 2024: $1,927 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385 · Education: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.95 |
| Education | $526.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $741.30 | 2023-2025 | Enhertu |
| Pfizer INC. | $317.58 | 2023-2024 | |
| Lilly USA, LLC | $293.05 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $270.12 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $240.53 | 2023-2024 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $217.72 | 2022-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $211.88 | 2023-2024 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $211.57 | 2023-2024 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $171.46 | 2024-2025 | Darzalex, Talvey, Rybrevant |
| Astellas Pharma US INC | $141.07 | 2023-2025 | Xtandi, Xospata |
| Aveo Pharmaceuticals, INC. | $119.09 | 2024 | |
| Genzyme Corporation | $89.84 | 2022-2024 | |
| Eisai INC. | $81.93 | 2023-2024 | |
| Sobi, INC | $80.56 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.45 | 2023-2024 | Fruzaqla, Ninlaro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.